Real-World Data Shows that Epidiolex Significantly Reduces Seizure Frequency in LGS and Dravet Syndrome
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Real-World Data Shows that Epidiolex Significantly Reduces Seizure Frequency in LGS and Dravet Syndrome

Seizures associated with conditions such as Dravet syndrome and Lennox-Gastaut syndrome (LGS) can be difficult to treat; these seizures may be treatment-averse and may not respond well to current anti-epileptic…

Continue Reading Real-World Data Shows that Epidiolex Significantly Reduces Seizure Frequency in LGS and Dravet Syndrome
Soticlestat Reduces Seizure Frequency in Dravet Syndrome, Study Shows
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Soticlestat Reduces Seizure Frequency in Dravet Syndrome, Study Shows

Both Dravet syndrome and Lennox-Gastaut syndrome (LGS) are characterized by frequent and often severe seizures. In many cases, those affected require multiple medications to manage their condition and prevent epileptic…

Continue Reading Soticlestat Reduces Seizure Frequency in Dravet Syndrome, Study Shows

Stoke Therapeutics and Acadia Pharmaceuticals Collaborate to Develop Medicines for Rare Neurodevelopmental Disorders

Stoke Therapeutics and Acadia Pharmaceuticals made a joint announcement this week through Business Wire of their collaboration in the development of RNA-based medicines to potentially treat rare neurodevelopmental disorders of…

Continue Reading Stoke Therapeutics and Acadia Pharmaceuticals Collaborate to Develop Medicines for Rare Neurodevelopmental Disorders
Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail
source: pixabay.com

Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Whole Plant Cannabis Succeeds in Rare Childhood Epilepsies Where CBD and Others Fail

Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome

The American Academy of Neurology recently held their annual meeting virtually to discuss the latest research in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). This meeting was held April 17th through 22nd,…

Continue Reading Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome
Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion
esudroff / Pixabay

Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion

  In mid-October, biopharmaceutical company Zogenix announced that its Dravet syndrome treatment FINTEPLA (fenfluramine) received a positive CHMP opinion. The CHMP is part of the European Medicines Agency (EMA). While…

Continue Reading Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion
Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
source: pixabay.com

Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

According to a story from BioSpace, the biopharmaceutical company Zogenix, Inc., has recently announced the release of results from a phase 3 clinical trial testing the company's drug fenfluramine (marketed…

Continue Reading Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome
source: pixabay.com

AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome

As reported in Dravet Syndrome News, in a new study, researchers created an artificial intelligence system which could diagnose epileptic conditions more rapidly and easily than existing systems. Epilepsy is…

Continue Reading AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome

With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two…

Continue Reading With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus
These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
EliasSch / Pixabay

These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies

According to a story from BioSpace, the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead…

Continue Reading These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE
source: pixabay.com

CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE

According to a story from BioPortfolio, the biopharmaceutical company GW Pharmaceuticals plc recently announced that its medicine Epidyolex has earned recommendation from the UK National Institute for Health and Care…

Continue Reading CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE